We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
+$295M
Cap. Flow
+$29.2M
Cap. Flow %
0.74%
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
3
INZY
Inozyme Pharma
INZY
+$21.9M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21.7M
5
HUM icon
Humana
HUM
+$20.7M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32M
3
CI icon
Cigna
CI
+$30.2M
4
AMGN icon
Amgen
AMGN
+$29.7M
5
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.05%
2 Consumer Staples 1.43%
3 Consumer Discretionary 0.93%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
76
Nkarta
NKTX
$162M
$16.3M 0.41%
+540,873
New +$15.9M
OSH
77
DELISTED
Oak Street Health, Inc.
OSH
$16M 0.41%
+300,000
New +$13.4M
ADAP
78
DELISTED
Adaptimmune Therapeutics
ADAP
$15.9M 0.4%
1,986,910
– –
QURE icon
79
uniQure
QURE
$3.11B
$15.2M 0.39%
413,433
+6,300
+2% +$258K
FOLD
80
DELISTED
Amicus Therapeutics
FOLD
$14.5M 0.37%
1,023,821
+7,000
+0.7% +$102K
CNMD icon
81
CONMED
CNMD
$1.5B
$14.2M 0.36%
180,000
– –
SPRO icon
82
Spero Therapeutics
SPRO
$70.6M
$13.8M 0.35%
1,236,256
+621,079
+101% +$7.35M
AKRO
83
DELISTED
Akero Therapeutics
AKRO
$13M 0.33%
423,040
+180,055
+74% +$6.29M
KYNB
84
Kyntra Bio
KYNB
$28.9M
$12.7M 0.32%
12,371
-247
-2% -$266K
ACCD
85
DELISTED
Accolade Inc
ACCD
$12.6M 0.32%
+325,000
New +$11.2M
APRE icon
86
Aprea Therapeutics
APRE
$8.11M
$12.5M 0.32%
25,915
– –
TBPH icon
87
Theravance Biopharma
TBPH
$877M
$12.2M 0.31%
824,018
-4,200
-0.5% -$78.7K
GWPH
88
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$11.6M 0.29%
119,188
-855
-0.7% -$98.4K
FUSN
89
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$11.4M 0.29%
947,541
+10,500
+1% +$144K
RIGL icon
90
Rigel Pharmaceuticals
RIGL
$776M
$11.4M 0.29%
474,289
-115,475
-20% -$2.84M
AUPH icon
91
Aurinia Pharmaceuticals
AUPH
$2.06B
$11.4M 0.29%
+772,569
New +$11.2M
ARVN icon
92
Arvinas
ARVN
$583M
$11.4M 0.29%
481,468
– –
OSW icon
93
OneSpaWorld
OSW
$2.65B
$11.3M 0.29%
1,740,000
– –
SYRE icon
94
Spyre Therapeutics
SYRE
$8.88B
$11.3M 0.29%
63,621
– –
TRIL
95
DELISTED
Trillium Therapeutics Inc.
TRIL
$11M 0.28%
770,918
+8,300
+1% +$82.8K
PRLD icon
96
Prelude Therapeutics
PRLD
$411M
$10.9M 0.28%
+360,263
New +$10.2M
TARA icon
97
Protara Therapeutics
TARA
$221M
$10.8M 0.27%
+643,622
New +$14.9M
CNST
98
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$10.4M 0.27%
515,680
– –
PRTA icon
99
Prothena Corp
PRTA
$471M
$10.2M 0.26%
1,025,207
+35,989
+4% +$433K
RYTM icon
100
Rhythm Pharmaceuticals
RYTM
$7.92B
$10.1M 0.26%
464,086
-48,025
-9% -$1.1M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rock Springs Capital Management held 163 positions worth $3.94B, up 8.1% from $3.65B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q3 2020 filing shows 20 new, 50 increased, 30 reduced and 15 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M.
  • Rock Springs Capital Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $22.4M increase.
  • Rock Springs Capital Management's biggest Q3 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $32M.
  • Rock Springs Capital Management fully exited Portola Pharmaceuticals, Inc. in Q3 2020, selling an estimated $41.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $3.94B portfolio in Q3 2020.
  • Rock Springs Capital Management opened 20 new positions and closed 15 in Q3 2020.
  • Rock Springs Capital Management's portfolio value rose 8.1% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.